The Janssen PRMT5 inhibitor, onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with high selectivity and potency (subnanomolar range, PRMT5-MEP-50 IC50=0.14 nM) under various conditions. While JNJ-64619178 binds non-covalently in the PRMT5 SAM and [...]
< 1 minute read
Nov. 26, 2021
Onametostat: A Selective Orally Pseudo-Irreversible PRMT5 Inhibitor
JNJ-64619178
pseudo-irreversible methyltransferase inh. oral, phase I, cancer from adenosine derivative library + opt. Molecular Cancer Therapeutics Janssen R&D
Loading...
